Cardiol Res
Cardiology Research, ISSN 1923-2829 print, 1923-2837 online, Open Access
Article copyright, the authors; Journal compilation copyright, Cardiol Res and Elmer Press Inc
Journal website http://www.cardiologyres.org

Case Report

Volume 2, Number 6, December 2011, pages 298-300


Thrombosis of A Prosthetic Mitral Valve After Withdrawal of Phenprocoumon Therapy

Andreas Wilkea, Christian M. Wendeb, Michael Horstc, Dietmar Steverdingd, e

aKardiologische Praxis Papenburg, Papenburg, Germany
bAbteilung Kardiologie, Marienkrankenhaus Papenburg, Papenburg, Germany
cAbteilung Kardiochirugie, Städtische Kliniken Oldenburg, Oldenburg, Germany
dNorwich Medical School, University of East Anglia, Norwich, UK
eCorresponding author: Dietmar Steverding, BioMedical Research Centre, Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK

Manuscript accepted for publication November 17, 2011
Short title: Prosthetic Heart Valve Thrombosis
doi: https://doi.org/10.4021/cr124w

Abstract▴Top 

Patients with prosthetic heart valves require lifelong oral anticoagulant therapy based on vitamin K antagonists. These patients may need interruption of their anticoagulant therapy if they have to undergo surgery. The clinical challenge is to identify patients who can safely undergo surgery while continuing their vitamin K antagonist treatment and those who have to take short-acting heparin as part of a bridging therapy. Here we present a case of a patient with a prosthetic mitral valve whose oral anticoagulant therapy was unnecessarily discontinued by the GP prior to an upcoming cataract surgery. As a result, the patient developed thrombosis of the prosthetic mitral valve which needed to be surgically replaced.

Keywords: Bridging therapy; Oral anticoagulant therapy; Prosthetic heart valve thrombosis

Introduction▴Top 

Oral anticoagulant therapy using vitamin K antagonists is a very effective treatment to prevent thromboembolic complications in many medical conditions [1]. However, managing these patients when they require temporary interruption of their anticoagulant therapy because of necessary surgery is a common clinical problem. In particular, withdrawal of phenprocoumon is associated with an increase in the risk of thromboembolic complications because of the long half-life of this drug [2]. To reduce this risk, clinicians often use bridging therapy with an anticoagulant that has a much shorter half life and is therefore more easily controlled. For example, low-molecular-weight heparin is frequently used in these cases as it has a rapid onset and offset of its action compared to vitamin K antagonists [3]. Here, we report a case where such a bridging therapy went wrong causing thromboembolic complications with the result that the patient needed reoperation.

Case Report▴Top 

A 70-year-old woman with a prosthetic mitral valve replacement (St. Jude Medical mechanical valve model 29MECJ-502; year 2002) presented herself at the Kardiologische Praxis Papenburg with dyspnoea and exhaustion. For preparation of an upcoming cataract operation, her GP discontinued her anticoagulant therapy with phenprocoumon several days ago. After three days of withdrawal of any anticoagulant medication, the GP started to treat the patient once daily with subcutaneous injections of 7500 units of unfractionated sodium heparin. The patient was under this anticoagulant therapy when she presented herself at the cardiac surgery. At that time, her INR value was 1.4.

Transthoratic echocardiography revealed a reduced mobility of the prosthetic mitral valve. On transoesophageal echocardiography, we confirmed the suspicion of a functional stenosed heart valve through blockage of the hinge-joint of one leaflet (Fig. 1). The patient was treated straightaway with subcutaneous injections of 8000 units of certoparin twice daily and was admitted to the hospital. Radioscopy confirmed the suspicion of a partially thrombosed mitral valve with obstruction of one leaflet of the bileaflet valve (Fig. 2). The damaged valve was surgically replaced with a bioprosthetic valve (Medtronic Mosaic Procine Bioprosthesis Model 310, diameter 31 mm). The excised valve clearly showed signs of deposits of thrombi on its rim (Fig. 3). From the atrial aspect, thrombotic deposits can be found on the hinge-joints and alongside one leaflet. Thrombotic material was also deposited on the ventricular side of the valve.

Figure 1.
Click for large image
Figure 1. Transoesophageal echocardiography showing reduced mobility of the prosthetic valve with functional stenosis. (A) Diastole. (B) Systole. (C) Colour Doppler of the diastole. The white and red arrows point to the mobile and immobile leaflets, respectively.

Figure 2.
Click for large image
Figure 2. Radioscopy. Only one leaflet of the bileaflet valves opens.

Figure 3.
Click for large image
Figure 3. Excised valve. Thrombotic deposits are clearly visible.
Discussion▴Top 

Surgery of patients with prosthetic heart valves demands a close monitoring of their coagulation status [4]. In the presented case, the approach of the GP was erroneous and led to the need for valve replacement in the patient [5]. Strictly speaking, the GP made two errors in the management of the patient (however, we have not spoken to the GP and therefore we do not know why the GP chose a particular option and for what reasons). First, there was no need to withdraw the anticoagulant medication for the upcoming cataract surgery in the first place [6]. The required retrobulbar anaesthesia could have been carried out under ongoing anticoagulant therapy without any problem. Alternatively, a topical anaesthesia via eye drops would have been possible. Second, even if there were good reasons to stop the anticoagulant medication, it was a poor choice to use unfractionated heparin at that dose and route of administration (subcutaneous injection of 7500 units) as bridging anticoagulation therapy. The pharmacokinetics of unfractionated heparin is unpredictable and it is very unlikely that sufficient amount of this anticoagulant agent would have been absorbed to provide effective dose from the subcutaneous injection. Instead, better controllable low-molecular-weight heparins are the anticoagulant of choice for bridging therapies [5, 7]. Before introducing any bridging therapy, e.g. the withdrawal of oral anticoagulant medicine and administration of low-molecular-weight heparins, the individual risk of thrombosis has to be considered. Medical disorders which need oral anticoagulant medication can be categorised into conditions with high (> 10%/year without anticoagulant therapy), medium (4 - 10%/year without anticoagulant therapy) and low (< 4% without anticoagulant therapy) thromboembolic risk [7]. Factors which increase the thromboembolic risk are atrial fibrillation with concomitant cardiac insufficiency, prosthetic heart valves, and recent (within the last month) arterial or venous thromboembolic events [5, 7]. The thromboembolic risk determines what course of bridging therapy is appropriate [8]. A scheme for bridging therapy with certoparin (Mono-Embolex®) as an example for anticoagulant patients with a high thromboembolic risk is shown in Table 1. Deviation from this scheme bears the risk of formation of thrombi including the consequences described in this case report. Two other examples of low-molecular-weight heparins that are suitable for bridging therapy are enoxaparin (Clexane®) and tinzaparin (Innohep®). For medical conditions with low thromboembolic risk, no bridging therapy is necessary if the anticoagulant medication is only discontinued for a short period of time [7]. Under these circumstances, a standard thrombosis prophylaxis appropriate for the particular surgery is sufficient.

Table 1.
Click to view
Table 1. Example for Bridging Therapy With Certoparin 8000
 

Acknowledgments

We would like to thank Dr Yoon Loke for critical reading of the manuscript.

Conflicts of Interest

The authors report no financial relationships or conflict of interest regarding the content herein.


References▴Top 
  1. Lemos Silva R, Carvalho de Sousa J, Calisto C, Braz Nogueira JM, Ravara L. Oral anticoagulant therapy. Fundamentals, clinical practice and recommendations. Rev Port Cardiol. 2007;26(7-8):769-788.
    pubmed
  2. Haustein KO, Hüller G. Pharmacokinetics of phenprocoumon. Int J Clin Pharmacol Ther. 1994;32(4):192-197.
    pubmed
  3. Kaatz S, Paje D. Update in bridging anticoagulation. J Thromb Thrombolysis. 2011;31(3):259-264.
    pubmed doi
  4. Leiria TL, Lopes RD, Williams JB, Katz JN, Kalil RA, Alexander JH. Antithrombotic therapies in patients with prosthetic heart valves: guidelines translated for the clinician. J Thromb Thrombolysis. 2011;31(4):514-522.
    pubmed doi
  5. Hoffmeister C, Bode H, Darius K, Huber K, Rybak K, Silber S. Unterbrechung antithrombotischer Behandlung (Bridging) bei kardialen Erkrankungen. Kardiologe. 2010;4(5):365-374.
  6. Jafri SM. Periprocedural thromboprophylaxis in patients receiving chronic anticoagulation therapy. Am Heart J. 2004;147(1):3-15.
    pubmed doi
  7. Bauersachs RM, Schellong S, Haas S, Gogarten W, Riess H, Omran H. Überbrückung der oralen Antikoagulation bei interventionellen Eingriffen. Dtsch Arztebl. 2007;104(18):A1237-A1244.
  8. Levi M, Eerenberg E, Kamphuisen PW. Periprocedural reversal and bridging of anticoagulant treatment. Neth J Med. 2011;69(6):268-273.
    pubmed


This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Cardiology Research is published by Elmer Press Inc.

 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Cardiology Research, bimonthly, ISSN 1923-2829 (print), 1923-2837 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.

This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.cardiologyres.org   editorial contact: editor@cardiologyres.org    elmer.editorial2@hotmail.com
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.


Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.